News

After Delay, Innate Immunotherapeutics’ MIS416 Trial For Secondary Progressive MS Therapy To Begin Enrolling in August

In spite of an eight week delay, New Zealand-based Innate Immunotherapeutics is still planning to enroll patients for its phase 2b clinical trial that will study the experimental drug MIS416 for secondary progressive MS. The clinical research organization (CRO) involved in the management of the trial informed the company about the delay,…

FDA Removes Partial Clinical Hold for CTP-354, Concert Pharmaceuticals’ Novel Drug for MS, Spasticity

The U.S. Food and Drug Administration (FDA) recently notified Concert Pharmaceuticals that the company had fulfilled all necessary preclinical toxicological tests for the oral therapy CTP-354 for the treatment of multiple sclerosis, spinal cord injury, and spasticity. The authorization to administer repeated doses of the compound, in excess of 6 mg per day,…

USC PhD Student Creates Project to Treat MS with Nanotechnology

A Ph.D. student at the University of Southern California (USC) Viterbi Ming Hsieh Department of Electrical Engineering, Kun Yue, is developing a model of selected brain circuits to study multiple sclerosis (MS) in an effort to develop a nanotechnology based treatment for the disease. Yue believes that new technology can lead…

Antihistamine Repurposed for Remyelination in Phase 2 Trial from UCSF

The University of California, San Francisco (UCSF) initiated a clinical trial to evaluate the antihistamine clemastine fumarate, manufactured by Novartis as Tavist, for its efficacy in treating multiple sclerosis patients. The laboratory of Dr. Jonah Chan, a professor of neurology at UCSF, used a high-throughput method to identify Tavist…

MS Care Costs Rose 60 Percent in 7 Years, According To Study

The main costs of care for multiple sclerosis (MS) patients continue to be driven predominantly by common MS “sequelae” — a condition that is the consequence of a previous disease or injury — according to a recent study from the BMC Health Services Research. However, in spite of cost drivers remaining steady,…

UB Team Finds a Way to Make Stem Cells into Myelinating Cells

Stem therapy to treat multiple sclerosis may benefit greatly from a new study published in Proceedings of the National Academy of Sciences by the laboratory of Fraser Sim, Ph.D., assistant professor of Pharmacology and Toxicology at University of Buffalo’s School of Medicine and Biomedical Sciences. Dr. Fraser’s…

Cleveland Clinic Researchers Find iPad A Powerful Multiple Sclerosis Assessment Tool

Tracking patients’ progress is a critical part of MS management, a process that can benefit from greater objective analysis. Researchers at the Cleveland Clinic have determined that tablet computers, which feature built-in technologies like accelerometers, gyroscopes, and touchscreens, when combined with appropriate software, can provide pretty good MS assessment capabilities.

Actavis Plans Generic Version of Acorda’s Multiple Sclerosis Drug Ampyra

Acorda Therapeutics recently announced receiving a notice letter from pharmaceutical company Actavis Plc indicating their plans to commercialize a generic version of Ampyra, Acorda’s multiple sclerosis treatment drug. Acorda claims that Actavis submitted a marketing approval application with the U.S. Food and Drug Administration (FDA) asking permission to develop and commercialize a new drug,…

Hilton Foundation Opens Submissions for Innovation Award in MS

The Conrad N. Hilton Foundation is accepting submissions for the first edition of the Marilyn Hilton Award for Innovation in Multiple Sclerosis Research, which will support novel and potentially paradigm-shifting research on Progressive Multiple Sclerosis (MS). The award will grant up to $6 million in funding to several projects over a four-year…

Roche Turns to MS Research on Agreement with Versant Ventures

The Swiss pharmaceutical company Roche recently announced a partnership agreement with California-based Inception Sciences and venture capital firm Versant Ventures. The three companies will work together to form a new company, Inception 5, which will be dedicated mostly to the development of therapies for multiple sclerosis. Inception 5’s research will focus…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here